Pfizer Inc  (PFE)
Other Ticker:  
Price: $28.9100 $-1.56 -5.120%
Day's High: $29.4 Week Perf: -4.08 %
Day's Low: $ 28.30 30 Day Perf: -5.24 %
Volume (M): 103,624 52 Wk High: $ 54.93
Volume (M$): $ 2,995,770 52 Wk Avg: $38.68
Open: $28.97 52 Wk Low: $28.30

 Market Capitalization (Millions $) 163,226
 Shares Outstanding (Millions) 5,646
 Employees 79,000
 Revenues (TTM) (Millions $) 68,537
 Net Income (TTM) (Millions $) 10,521
 Cash Flow (TTM) (Millions $) 1,895
 Capital Exp. (TTM) (Millions $) 3,864

Pfizer Inc
Pfizer Inc.,'is a research-based, global pharmaceutical company. We discover, develop, manufacture and market leading prescription medicines for humans and animals as well as many of the world's best-known consumer healthcare products.

The Company was incorporated under the laws of the State of Delaware on June' 2, 1942.

We operate in three business segments: Pharmaceutical, Consumer Healthcare and Animal Health.

We also operate several other businesses, including the manufacture of empty soft-gelatin capsules, contract manufacturing, bulk pharmaceutical chemicals and diagnostics.

We have significant operations outside the United States. They are conducted both through our subsidiaries and through distributors, and involve the same business segments - Pharmaceutical, Consumer Healthcare and Animal Health - as our U.S. operations.

In our global Pharmaceutical business, we promote our products to health care providers such as doctors, nurse practitioners, physician assistants, pharmacists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. Through our marketing organizations, we explain the approved uses and advantages of our products to health care providers. We also market directly to consumers in the U.S. through direct-to-consumer print and television advertising. In addition, we sponsor general advertising to educate the public about our innovative medical research.

Our operations include several pharmaceutical sales organizations. Each sales organization markets a distinct group of products. Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies.

We seek to gain access to health authority, PBM and MCO formularies (lists of recommended or approved medicines and other products) and reimbursement lists by demonstrating the qualities and treatment benefits of our products. We also work with MCOs and PBMs to assist them with disease management, patient education and other tools that help their medical treatment routines. For example, we sponsor a program offered by the State of Florida Agency for Health Care Administration that is designed to help manage chronic diseases among Florida's Medicaid population.

Our Consumer Healthcare business primarily uses its own representatives to directly promote its products, including marketing certain products directly to professionals using a professional detail force. We also use print and television consumer advertising and offer sales incentives such as coupons. Our consumer products are sold through various retailers.

Our Animal Health business also uses its own sales organization to promote its products. Its advertising and promotion are generally targeted to health professionals, directly and through medical journals. Animal health and nutrition products are sold through veterinarians, drug wholesalers, distributors and retail outlets as well as directly to users. Where appropriate, these products are also marketed through print and television advertising.


Competition is intense in all of our businesses and includes many large and small competitors. The principal means of competition vary among product categories and business groups. However, efficacy, safety, patients' and customers' ease of use and cost effectiveness are important factors for success in all of our principal businesses.

Our human pharmaceutical business is the largest in the world. We compete with other worldwide research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers.

We focus on unmet medical needs and therapeutic improvements. Our emphasis on innovation has led to our multi-billion-dollar research and development investments over the past decade.

In recent years, a comparison of the total cost of medical treatments using pharmaceuticals versus alternative treatments for the same condition has become an important basis of competition. MCOs and PBMs look to cost advantages as well as medical benefits in making their drug formulary decisions.

Our pharmaceutical sales and marketing organization is a valuable competitive asset. Our salespeople's ability to reach medical professionals with information about our products helps us respond to competitive efforts and launch new products.

Our consumer healthcare business is one of the largest in the world. However, many other companies, large and small, manufacture and sell one or more products that are similar to our consumer healthcare products. Sources of competitive advantage include product quality and efficacy, brand identity, advertising and promotion, product innovation, broad distribution capabilities and price. Significant expenditures for advertising, promotion and marketing are generally required to achieve and maintain both consumer and trade acceptance of consumer products.

While our animal health business is the largest in the world, many other companies offer competitive products. Altogether, there are hundreds of producers of animal health products throughout the world. The principal methods of competition vary somewhat depending on the particular product. They include product innovation, quality, service, effective promotion to veterinary professionals and consumers and price. We promote our products directly through our sales representatives as well as through advertising.

Managed Care Organizations

The growth of MCOs in the U.S. has been a major factor in the competitive make-up of the health care marketplace. A substantial portion of the U.S. population now participates in some version of managed care. Because of the size of the patient population covered by MCOs, marketing of prescription drugs to them and the PBMs that serve many of those organizations has become important to our business.

MCOs can include medical insurance companies, medical plan administrators, health-maintenance organizations, alliances of hospitals and physicians and other physician organizations. The purchasing power of MCOs has been increasing in recent years due to their growing numbers of enrolled patients. At the same time, those organizations have been consolidating into fewer, even larger entities. This enhances their purchasing strength and importance to us.

The growth of MCOs has increased pressure on drug prices. A major objective of MCOs is to contain and, where possible, reduce health care expenditures. They typically use formularies, volume purchases and long-term contracts to negotiate discounts from pharmaceutical providers. They use their purchasing power to bargain for lower supplier prices. They also emphasize primary and preventive care, out-patient treatment and procedures performed at doctors' offices and clinics. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed. Since the use of certain drugs can prevent the need for hospitalization, professional therapy or even surgery, such drugs can become favored first-line treatments for certain diseases.

As discussed above in Marketing, MCOs and PBMs typically develop formularies to reduce their cost for medications. Formularies can be based on the prices and therapeutic benefits of the available products. Due to their generally lower cost, generic medicines are often favored. The breadth of the products covered by formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular medical problems. MCOs use a variety of means to encourage patients' use of products listed on their formularies.

Exclusion of a product from a formulary can lead to its sharply reduced usage in the MCO patient population. Consequently, pharmaceutical companies compete aggressively to have their products included. Where possible, companies compete for inclusion based upon unique features of their products, such as greater efficacy, better patient ease of use or fewer side effects. A lower overall cost of therapy is also an important factor. Products that demonstrate fewer therapeutic advantages must compete for inclusion based primarily on price. We have been generally, although not universally, successful in having our major products included on MCO formularies.

The impact of MCOs on drug prices and volumes may increase as the result of their role in negotiating on behalf of Medicare beneficiaries in connection with the recently enacted, limited out-patient drug benefit under Medicare, as discussed below under Government Regulation and Price Constraints.

Another way we address the interests of MCOs is by developing disease-management programs. These programs can be attractive to MCOs by improving patient communications and compliance with dosage directions, which are important for effective disease treatment. They can help MCOs address various aspects of disease management, such as prevention, diagnosis and treatment of certain diseases, including use of pharmaceutical products. This comprehensive approach can improve the quality of care and lower costly complications of chronic diseases. As noted above in Marketing, one such program, which is sponsored by us and offered by the State of Florida Agency for Health Care Administration, is designed to help manage chronic diseases among Florida's Medicaid population.

Generic Products

One of the biggest competitive challenges that we face in the U.S. and that is growing internationally is from generic pharmaceutical manufacturers. Upon the expiration or loss of patent protection for a product, we can lose the major portion of sales of that product in a very short period. Generic competitors operate without our large research and development expenses and our costs of conveying medical information about the product to the medical community. In addition, the FDA approval process exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, and allows generic manufacturers to rely on the safety and efficacy of the pioneer product. Generic products need only demonstrate a level of availability in the bloodstream equivalent to that of the pioneer product. This means that, after we have borne the expenses of discovering, developing and testing a medicine for safety and efficacy, obtaining regulatory approval and informing the medical community about its therapeutic benefits, generic competitors can market a competing version of our product after the expiration or loss of our patent and charge much less.

   Company Address: 66 Hudson Boulevard East New York 10001 NY
   Company Phone Number: 733-2323   Stock Exchange / Ticker: NYSE PFE
   PFE is expected to report next financial results on February 22, 2024.

Customers Net Income grew by PFE's Customers Net Profit Margin grew to

4.19 %

4.02 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV        3.11% 
ABT        2.11% 
BMY        2.2% 
JNJ        4.69% 
LLY   -1.27%    
MRK        2% 
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.


Pfizer Inc's Segments
Cardiovascular & metabolic diseases
 Segment     of total Revenue
Central nervous system disorders
 Segment     of total Revenue
Arthritis & pain
 Segment     of total Revenue
Infectious & respiratory diseases
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Endocrine disorders
 Segment     of total Revenue
All other
 Segment     of total Revenue
Total Pharmaceutical
 Segment     of total Revenue
Consumer Healthcare and Vaccines
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Pfizer Inc announced annual revenue outlook on

Earnings Outlook
Pfizer Inc issued annual earnings guidance on

Geographic Revenue Dispersion
United States


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com